SPH 3348
Alternative Names: I-020; SPH-3348Latest Information Update: 28 Oct 2024
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Aug 2024 Shanghai Pharmaceuticals Holding completes a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (PO, Tablet) (NCT06605599)
- 30 Jul 2024 Shanghai Pharmaceuticals Holding completes a phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (PO, Tablet) (NCT05088070)
- 15 Jul 2024 Shanghai Pharmaceuticals Holding initiates enrolment in a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (PO, Tablet) (NCT06605599)